{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:46:05Z","timestamp":1777434365826,"version":"3.51.4"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ebiom.2019.06.024","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T02:05:22Z","timestamp":1561169122000},"page":"22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Translating palbociclib to the clinic for DIPG - What is truly achievable?"],"prefix":"10.1016","volume":"45","author":[{"given":"Laura","family":"Franshaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tsoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta M.S.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.06.024_bb0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ebiom.2019.04.043","article-title":"Potent anti-tumor efficacy of palbociclib in treatment-naive H3.3K27M-mutant diffuse intrinsic pontine glioma","volume":"43","author":"Sun","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2019.06.024_bb0010","author":"FDA"},{"issue":"2","key":"10.1016\/j.ebiom.2019.06.024_bb0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2019.06.024_bb0020","series-title":"Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","author":"Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.ebiom.2019.06.024_bb0025","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0666","article-title":"Predictors of success of phase II pediatric oncology clinical trials","author":"Franshaw","year":"2019","journal-title":"Oncologist"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419304050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419304050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:57:48Z","timestamp":1762455468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419304050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":5,"alternative-id":["S2352396419304050"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.024","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating palbociclib to the clinic for DIPG - What is truly achievable?","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.04.043","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}